U lcerative colitis (UC) and Crohn's disease are inflammatory bowel diseases (IBDs) that are chronic, idiopathic disorders of the gastrointestinal tract that are believed to result from a complex interplay between genetic, environmental, immune, and microbial factors. 1, 2 Vitamin D has an emerging role as an environmental factor in the pathogenesis of autoimmune disorders including IBD. 3, 4 The clinical significance of vitamin D has extended beyond its function in calcium homeostasis and bone metabolism, with mounting evidence supporting its role in regulating immune responses. 5, 6 Vitamin D receptors are found to be expressed on a variety of immune cells and indeed vitamin D has numerous and multifaceted effects on the immune system. Vitamin D decreases the generation of proinflammatory T-helper 1 responses and increases the levels of anti-inflammatory T-helper 2 cells. 7 Vitamin D promotes self-tolerance by inhibition of dendritic cell differentiation and maturation 8, 9 and increases the number and function of T-regulatory cells. 10, 11 Vitamin D also has been implicated in modulating the ability of human macrophages to kill intracellular bacteria 12 as well as protecting the epithelial mucosal barrier in intestinal inflammation. 13 Genetic polymorphisms in the vitamin D receptor (VDR) have been associated with susceptibility and disease severity in patients with ulcerative colitis and Crohn's disease. 14, 15 In mice models of experimental colitis, VDR knockout mice developed severe inflammation of the gastrointestinal tract and administration of the active form of vitamin D (1,25D3) attenuated this effect of VDR deficiency on the development of severe colitis. 16 In human studies, vitamin D levels are related inversely to disease severity in patients with IBD. In 2 cross-sectional studies, vitamin D deficiency was associated with disease activity in both ulcerative colitis and Crohn's disease. 17, 18 One retrospective study showed the association between vitamin D deficiency and lower quality-of-life indices and increased disease activity in patients with Crohn's disease, but not in patients with UC. 19 Several other studies in Crohn's disease patients have shown that higher vitamin D status was associated with a reduced risk of disease development, normalization of vitamin D levels reduced risk of surgery, and that vitamin D levels increase and are responsive to treatment with biologics. [20] [21] [22] Prospective studies exploring the effects of vitamin D on clinical outcomes and relapse are lacking, especially in patients with ulcerative colitis. One small prospective cohort of patients with mild to moderate Crohn's disease showed that increasing the serum vitamin D levels to normal levels was associated with decreased disease index scores. 23 In a randomized clinical trial of vitamin D supplementation in Crohn's disease patients, there was a trend toward a reduced risk of clinical relapse, but ultimately was not significant. 24 Although vitamin D status has been implicated to correlate with disease severity, the clinical significance of low vitamin D levels among patients with ulcerative colitis in clinical remission is unclear. We thus aimed to explore the effect of vitamin D levels on risk of relapse in patients with UC in clinical remission. We also assessed the correlation between vitamin D levels and the presence of baseline endoscopic and histologic inflammation.
Materials and Methods

Study Design and Patient Enrollment
We conducted a prospective study of patients with UC in clinical remission, with a Simple Clinical Colitis Activity Index (SCCAI) of 2 or less (Supplementary Figure 1) , 25, 26 who were recruited after a surveillance colonoscopy from the Inflammatory Bowel Disease Center at Beth Israel Deaconess Medical Center, Harvard Medical School (Boston, MA) from 2009 to 2012. The study was approved by the Beth Israel Deaconess Medical Center Institutional Review Board under protocol 2009P000314. From a cohort of 170 enrolled subjects, 70 had a baseline serum sample collected at the time of index colonoscopy. After the study follow-up period was completed, blinded investigators (J.G. and S.M.) measured serum vitamin D levels in these de-identified samples. Age, sex, ethnicity, smoking status, creatinine level, duration of disease, extent of disease, relevant medications (current nonsteroidal anti-inflammatory drugs, current mesalamine, current 6-mercaptopurine/ azathioprine, current anti-tumor necrosis factor-a, steroids in the past year, and vitamin D supplementation), and season of enrollment were recorded for each patient. Baseline laboratory values (white blood cell count, hematocrit level, erythrocyte sedimentation rate, and C-reactive protein level) also were obtained. We did not assess for baseline dietary vitamin D intake, initiation of vitamin D supplementation during the follow-up period, or actively supplement patients with vitamin D based on baseline levels.
Assessment of Baseline Endoscopic and Histologic Inflammation and Clinical Relapse
Each enrolled patient had a clinically indicated surveillance colonoscopy. During the index colonoscopy, endoscopic activity was classified using the sigmoidoscopy subscore of the Mayo activity index based on the most inflamed segment of the colon. 27 Histologic activity in all segments was classified using the Geboes score by a gastrointestinal pathologist blinded to endoscopic scores. 28 For each patient, a total Geboes score was assigned to biopsy specimens from each colonic segment and the highest score (most inflamed segment) was used as the cumulative histologic score. In our study, we defined endoscopic inflammation as a Mayo endoscopic score of 2 or greater. Histologic inflammation was defined as a Geboes histologic score of 3 or greater. Clinical relapse during the follow-up period was defined as a SCCAI score greater than 2, medication intensification, or UC-related hospitalization at any time during our follow-up period of 12 months. Medication intensification was defined by an increase in dose of the current regimen, addition of another medication, or change in class of medication as a result of symptom relapse.
Vitamin D Measurement and Receiver Operator Characteristic Curve
Serum vitamin D levels (25(OH)D) were measured by using a commercial enzyme-linked immunosorbent assay kit (Calbiotech, San Diego, CA) according to the manufacturer's instructions. A receiver operating characteristic curve of vitamin D levels for the outcome of clinical relapse was constructed. A vitamin D level threshold of 35 ng/mL or less was determined to have the greatest association for risk of clinical relapse in univariate and multivariate analyses (Supplementary Table 1) , and thus was chosen as our threshold level for further analyses. We compared the risk of clinical relapse among patients with a vitamin D level of 35 ng/mL or less vs a level greater than 35 ng/mL. To account for seasonal variations in vitamin D levels in New England, the year was dichotomized to a low sunlight season (SeptemberFebruary) and a high sunlight season (March-August).
Sunlight season was included as a covariate in our univariate analysis for risk of clinical relapse.
Data Analysis
The rate of clinical relapse, predictive value of clinical variables on the primary outcome, odds ratio (OR) with its 95% confidence interval (CI), and P values were assessed using JMP 11.0 (SAS Institute, Inc, Cary, North Carolina). Dichotomous variables were analyzed for outcomes using the chi-square test or the Fisher exact test where appropriate, and continuous variables were analyzed using t tests if normally distributed, or the Wilcoxon test for non-normal data. Correction for multiple testing was included. All variables were analyzed initially in a univariate fashion to determine their association with clinical relapse. P values of factors that showed evidence of an effect on clinical relapse (P < .05) then were analyzed on multivariate regression analysis. Given that mucosal healing has been associated with a risk of clinical relapse in patients with ulcerative colitis, 29, 30 we constructed models accounting for the individual effects of endoscopic and histologic inflammation. We also performed a subgroup analysis restricted to patients with both clinical (SCCAI 2) and endoscopic (Mayo endoscopic score 1) remission while accounting for the confounding effects of underlying histologic inflammation (Geboes grade ! 3). Finally, we also performed a time-to-event analysis to detect a difference in the time to clinical relapse among patients with vitamin D level of 35 ng/mL or less vs vitamin D levels greater than 35 ng/mL. For our multivariate analysis, model building was based on forward stepwise logistic regression, with a P value of .05 required for entry. All figures were generated using GraphPad Prism (version 5.0; GraphPad Software, Inc, La Jolla, CA). Table 1 details the baseline phenotype of the enrolled cohort. The mean serum vitamin D level in the cohort was 44 ng/mL (standard deviation, AE29). Only 8 patients (11.4%) used steroids in the past year. Vitamin D supplementation was reported by 42 patients (60%). Among the 70 patients enrolled, endoscopic inflammation was present in 9 patients (13%), whereas histologic inflammation was present in 32 patients (46%) at baseline. A multivariate analysis of the effects of clinical variables on the presence of baseline endoscopic or histologic inflammation highlighted that a vitamin D level of 35 ng/mL or less was associated independently with an increased presence of endoscopic inflammation (OR, 1.29; 95% CI, 1.07-1.85; P < .01) or histologic inflammation (OR, 1.46; 95% CI, 1.13-1.88; P ¼ .005) at baseline.
Results
Baseline Patient Characteristics
Vitamin D Levels and Receiver Operator Characteristic Curve
All patients who later relapsed had a SCCAI greater than 2 at follow-up evaluation. Clinical relapse outcomes in our cohort included the following: SCCAI greater than 2 alone (N ¼ 5), SCCAI greater than 2 with resulting medication intensification (N ¼ 13), and SCCAI greater than 2 with resulting medication intensification and hospitalization (N ¼ 2). As shown in Figure 1 , the mean baseline vitamin D level was lower in those who later relapsed (29.5 ng/mL), than those who did not (50.3 ng/mL; P ¼ .001). A receiver operating characteristic curve of baseline serum vitamin D levels for the outcome of 12-month clinical relapse had an area under the curve of 0.72 (P < .01) (Figure 2 ). A serum vitamin D level of 35 ng/mL or less had a sensitivity of 70% (95% CI, 
Vitamin D Threshold and Risk of Clinical Relapse
The rate of clinical relapse over 12 months for patients with a vitamin D level of 35 ng/mL or less vs patients with a vitamin D level greater than 35 ng/mL was 20% vs 9% (P ¼ .003), respectively. (Figure 3 ). In our multivariate-effects model, a baseline vitamin D level of 35 ng/mL or less was associated with an increased risk of clinical relapse (OR, 1.25; 95% CI, 1.01-1.56; P ¼ .044) even after adjusting for the effects of baseline histologic inflammation (Table 3) .
Discussion
In this prospective cohort study of 70 patients with ulcerative colitis, we showed that vitamin D levels are associated with baseline endoscopic and histologic inflammation severity during clinical remission, and are associated independently with the longitudinal risk of clinical relapse. These results suggest that vitamin D status is linked not only to current disease severity, but also has an impact on future risk of clinical relapse. This was a prospective study showing the effect of vitamin D levels during remission on clinical outcomes among patients with ulcerative colitis. There have been few prospective studies exploring the role of vitamin D on ulcerative colitis clinical outcomes. One analysis of an epidemiologic cohort by Ananthakrishnan et al 21 showed that low vitamin D levels was associated with a clinical relapse in the form of an increased risk of hospitalizations and surgeries. The results of our study are consistent with their finding that low vitamin D level predisposes patients to clinical relapse. However, their study did not control for UC disease severity or account for the effect of baseline inflammation in their multivariate analysis. Our study differs in that we restricted enrollment only to patients in clinical remission and adjusted for confounding effects of endoscopic and histologic inflammation in our analyses.
Previous studies also have shown that vitamin D levels are related inversely to UC disease activity. These studies of disease activity were based mainly on symptom scores and quality-of-life surveys. 18, 19, 31 Our study supports these previous findings that vitamin D is a marker of disease activity in UC and adds further to the literature by showing that vitamin D levels also reflect inflammatory activity at the endoscopic and histologic level beyond the clinical phenotype. Taken together, low serum vitamin D levels may be a useful biomarker for the detection of inflammation in UC patients in the absence of significant clinical symptoms.
Our finding that low vitamin D levels increases the risk of clinical relapse in UC patients in remission may be interpreted in several ways. One explanation is that the immunoprotective and anti-inflammatory properties of vitamin D diminishes with lower levels and this leads directly to subsequent inflammation and clinical relapse. Another explanation is that low vitamin D levels was an effect of increased disease activity and that the risk of clinical relapse was mediated through the effects of baseline inflammation. Low baseline vitamin D levels measured in our cohort were not caused by clinical disease activity because the patients enrolled in our study were in clinical remission. Although a subset of patients in our cohort had endoscopically and histologically active disease, our models adjusted for the effect of this baseline inflammation in our analysis. We also performed a subgroup analysis restricted only to patients in clinical and endoscopic remission, and after adjusting for histologic inflammation in our multivariate analysis, low vitamin D level still was associated with the risk of clinical relapse. Thus, our results show that low vitamin D level impacts risk of clinical relapse independent of subclinical inflammation.
Our study had several major strengths. First, our study was prospective and provided clarity of temporal sequence regarding our exposure of low vitamin D levels and outcome of clinical relapse. Second, our study was blinded: investigators measuring baseline serum vitamin D levels were blinded to subsequent relapse status to avoid selection bias at time of analysis and, likewise, our investigators assessing relapse during follow-up periods were blinded to baseline vitamin D levels. Third, our cohort was limited to UC patients in clinical remission, which allowed us to isolate the independent effects of vitamin D levels on risk of clinical relapse. Fourth, vitamin D status was based on direct vitamin D measurements from serum obtained at time of enrollment rather than from International Classification of Diseases, 9th revision, codes for vitamin D deficiency, random vitamin D values from the medical record, or from estimates of serum vitamin D calculated from diet, physical activity, and other predictors of vitamin D levels. Finally, our study focused solely on UC patients, a population that warrants greater attention regarding the clinical role of vitamin D. Generalizations regarding the effect of vitamin D on inflammatory bowel disease as a group may not be appropriate because of the genetic and immunologic differences in the pathogenesis of ulcerative colitis and Crohn's disease.
Our study had several limitations that merit attention. First, our sample size was small and may not be representative of the general UC population. Furthermore, the generalizability of our findings was limited only to UC patients in remission. Second, our study was based on a single measurement of serum vitamin D at time of enrollment, which may not reflect a patient's baseline levels and does not take into account the possibility of fluctuations over the course of 12 months. One large scale epidemiologic study by Jorde et al 32 involving longterm tracking of serum vitamin D levels acknowledged that although there are fluctuations in serum vitamin D levels, they are unlikely to have substantial improvements over time. Their study supported the use of a single serum vitamin D measurement to predict future health outcomes. Third, our study was observational and thus was limited by the inability to account for potential unmeasured confounders. In particular, our study did not take into account baseline dietary vitamin D intake, body mass index, physical activity, parathyroid hormone levels, malabsorptive conditions, medications that affect vitamin D levels, or adherence to medical therapy. Finally, although our cohort enrolled patients with clinically quiescent UC, we did not restrict our enrollment to patients with endoscopic and histologic remission, which raises the possibility that subclinical inflammation rather than low vitamin D levels is contributing to risk of relapse. However, we adjusted for the confounding effects of baseline endoscopic and histologic inflammation in our subgroup analysis and multivariate models.
The results of our study have several clinical implications. First, although currently not part of regular surveillance and standard of care in ulcerative colitis patients, our findings support the need for routine measurement of serum vitamin D levels. Second, our study suggests a role of low vitamin D as a maker of endoscopic and histologic inflammation in the absence of significant clinical symptoms, which may in turn be used to risk-stratify patients. Third, our findings provide a rationale for vitamin D supplementation in maintenance therapy in patients with ulcerative colitis. Maintaining serum vitamin D levels greater than specified thresholds during periods of clinical remission may be protective against subsequent clinical relapse.
In conclusion, our study provides evidence that low vitamin D levels ( 35 ng/mL) correlate with endoscopic and histologic inflammation and are associated with an increased risk of subsequent clinical relapse during periods of clinical remission. Vitamin D is an affordable, accessible, and relatively nontoxic supplement that may have protective effects in the maintenance of clinical remission in patients with ulcerative colitis. Clinical trials of vitamin D therapy to obtain vitamin D levels above this threshold should be considered to definitively establish its impact on ulcerative colitis outcomes.
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